Results 261 to 270 of about 291,785 (296)
Some of the next articles are maybe not open access.
Delivery Strategies for Immune Checkpoint Blockade
Advanced Healthcare Materials, 2018AbstractImmune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers.
Qian Chen +4 more
openaire +2 more sources
Combining chemotherapy and immune checkpoint blockade
Current Opinion in Urology, 2016Immune checkpoint blockade results in durable responses in a subset of patients with advanced urologic tumors. However, the majority of patients do not respond to single agent therapy raising the hypothesis that combination regimens may extend the benefits of immune checkpoint blockade to an even broader patient population.
Ana, Collazo-Lorduy, Matthew D, Galsky
openaire +2 more sources
Immunologic Checkpoint Blockade in Lung Cancer
Seminars in Oncology, 2015Despite the availability of radiotherapy, cytotoxic agents, and targeted agents, a high unmet medical need remains for novel therapies that improve treatment outcomes in patients with lung cancer who are ineligible for surgical resection. Building upon the early promise shown with general immunostimulatory agents, immuno-oncology is at the forefront of
Martin, Reck, Luis, Paz-Ares
openaire +2 more sources
Checkpoint Blockade for the Treatment of Advanced Melanoma
2015Immunotherapy with immune checkpoint inhibition has been improving the outcomes of patients with many different types of malignancies. Immune checkpoint inhibition has been most extensively studied in patients with advanced melanoma and there are three FDA approved antibodies already widely used in clinical practice (ipilimumab, nivolumab, and ...
Margaret K, Callahan +2 more
openaire +2 more sources
Microbiome dynamics in immune checkpoint blockade
Trends in Endocrinology & MetabolismImmune checkpoint blockade (ICB) is one of the leading immunotherapies, although a variable extent of resistance has been observed among patients and across cancer types. Among the efforts underway to overcome this challenge, the microbiome has emerged as a factor affecting the responsiveness and efficacy of ICB.
Chae Won Kim +2 more
openaire +2 more sources
Adjuvant immune checkpoint blockade revisited
The Lancet Oncology, 2023Sahar Barjesteh, van Waalwijk van Doorn-Khosrovani +6 more
openaire +2 more sources